Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection

被引:10
|
作者
Armstrong, Emily A. [1 ]
Beal, Eliza W. [2 ]
Shah, Manisha [3 ]
Konda, Bhavana [3 ]
Abdel-Misih, Sherif [2 ]
Ejaz, Aslam [2 ]
Dillhoff, Mary E. [2 ]
Pawlik, Timothy M. [2 ]
Cloyd, Jordan M. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Surg, Div Surg Oncol, Columbus, OH 43210 USA
[3] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
关键词
Neuroendocrine tumor (NET); carcinoid; hepatectomy; radiomics; prognosis; PROGNOSTIC-FACTORS; TUMORS; MANAGEMENT; THERAPY; EPIDEMIOLOGY; CHEMOEMBOLIZATION; DIFFERENTIATION; ENHANCEMENT; NEOPLASMS; SURVIVAL;
D O I
10.21037/hbsn.2019.06.02
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Previous research has demonstrated that specific radiographic criteria, including the presence of calcifications and the enhancement pattern on computed tomography (CT) imaging, correlates with clinicopathologic features and outcomes of patients with gastroenteropancreatic neuroendocrine tumors (NET). We sought to investigate whether these radiographic characteristics were prognostic among patients with neuroendocrine liver metastases (NELM) undergoing surgical resection. Methods: The preoperative contrast-enhanced CT scans of all patients who underwent resection of NELM at a single institution between 2000-2015 were retrospectively reviewed. The presence of calcifications was determined on non-contrast phase imaging. Enhancement on the arterial phase scan was categorized as hyperenhancing, hypoenhancing, or mixed. Relevant clinicopathologic characteristics as well as recurrence-free survival (RFS) and overall survival (OS) were compared between groups. Results: Among 82 patients who underwent resection of NELM, 57 had available data on calcifications while 51 had data available on arterial enhancement patterns. Among all patients, median age was 58 (IQR: 47-63) and the majority were female (N=48, 59.5%). The most common primary tumor locations were pancreas (N=25, 30.5%) and small bowel (N=27, 32.9%). The most commonly performed operations were right hepatectomy (N=29, 35.4%), bisegmentectomy (N=15, 18.3%), and segmentectomy (N=14, 17.1%). Median tumor number was 4 (IQR: 2-9), median Ki-67 was 5% (IQR: 2-10%), and median size of the largest liver metastasis was 4.5 (IQR: 2.8-7.7) cm. Twelve (21%) patients had tumor calcifications. Among patients with and without calcifications there were no differences in demographics, clinicopathologic characteristics, RFS (P=0.772) or OS (P=0.095). Arterial enhancement was hypoenhancing in 23 (45.1%), hyperenhancing in 10 (19.6%), and mixed in 18 (35.3%). Similarly, there were no differences between arterial enhancement groups in demographics, clinicopathologic characteristics, RFS (P=0.618) or OS (P=0.268). Conclusions: Radiographic characteristics on contrast-enhanced CT are not associated with the outcomes of patients undergoing resection of NELM. Future investigations should evaluate the prognostic impact of functional neuroendocrine imaging.
引用
收藏
页码:1 / +
页数:13
相关论文
共 50 条
  • [31] Neuroendocrine Liver Metastases
    Reddy, Srinevas K.
    Clary, Bryan M.
    SURGICAL CLINICS OF NORTH AMERICA, 2010, 90 (04) : 853 - +
  • [32] Neuroendocrine Liver Metastases
    Bargellini, Irene
    Vivaldi, Caterina
    Lorenzoni, Giulia
    Fornaro, Lorenzo
    Crocetti, Laura
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 42 (07) : 1053 - 1054
  • [33] Simultaneous resection for neuroendocrine tumors with synchronous liver metastases (SNTLM)
    Kolesnik, O.
    Lukashenko, A.
    Ostapenko, N.
    Chorna, N.
    Patsko, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 99 - 99
  • [34] Outcome of liver resection for non-colorectal and non-neuroendocrine liver metastases
    Pine, James
    Sanyal, Sudip
    Chhabra, Deepak
    Dave, Rajiv
    Hidalgo, Ernest
    Attia, Magdy
    Prasad, Raj
    Lodge, Peter
    Toogood, Giles
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 12 - 12
  • [35] Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases
    Gurusamy, Kurinchi Selvan
    Ramamoorthy, Rajarajan
    Sharma, Dinesh
    Davidson, Brian R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [36] Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria
    Ruzzenente, A.
    Bagante, F.
    Aldrighetti, L.
    Ercolani, G.
    Giuliante, F.
    Ferrero, A.
    Grazi, G.
    Guglielmi, A.
    Iacono, C.
    NEUROENDOCRINOLOGY, 2018, 106 : 284 - 284
  • [37] Outcome of liver resection for small bowel neuroendocrine tumour metastases
    Polkinghorne, M. D.
    Krige, J. E. J.
    Jonas, E.
    Kotze, U. K.
    Bernon, M. M.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2018, 56 (04) : 14 - 18
  • [38] NEUROENDOCRINE METASTASES OF THE LIVER
    IHSE, I
    PERSSON, B
    TIBBLIN, S
    WORLD JOURNAL OF SURGERY, 1995, 19 (01) : 76 - 82
  • [39] LIVER RESECTION FOR NEUROENDOCRINE TUMORS LIVER METASTASES IN TRANSPLANTABLE PATIENTS WITHIN THE MILAN CRITERIA
    Ruzzenente, Andrea
    Bertuzzo, Francesca
    Bagante, Fabio
    Aldrighetti, Luca
    Ercolani, Giorgio
    Giuliante, Felice
    Ferrero, Alessandro
    Grazi, Gian Luca
    Ciangherotti, Andrea
    Guglielmi, Alfredo
    Iacono, Calogero
    GASTROENTEROLOGY, 2018, 154 (06) : S1284 - S1284
  • [40] Long-Term Outcomes Following 90YRadioembolization of Neuroendocrine Liver Metastases
    Wong, Thomas Y.
    Zhang, Kevin
    andhi, Ripal
    Collins, Zach
    O'Hara, Ryan
    Wang, Eric
    Vaheesan, Kirubahara
    Siskin, Gary
    Matsuoka, Lea
    Sze, Daniel Y.
    Kennedy, Andrew S.
    D'Souza, Donna
    Brown, Daniel B.
    PANCREAS, 2022, 51 (03) : E42 - E42